TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Adding Clopidogrel to Aspirin or Use of Metoprolol in Myocardial Infarction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients presenting with ST elevation, left bundle branch block or ST depression within 24 hours of the onset of the symptoms of suspected acute MI~Exclusion Criteria:~* clear indications for, or contraindications to, any of the study treatments

- Gender: ALL
- Minimum Age: 0 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed acute symptomatic DVT, i.e. proximal or extensive calf-vein thrombosis involving at least the upper third part of the calf veins, without concomitant symptomatic PE~* Written informed consent~Exclusion Criteria:~* Legal lower age limitations (country specific)~* Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of DVT~* Other indication for VKA than PE/DVT~* More than 36 hours pre-randomization treatment with therapeutic dosages of (LMW) heparin or more than a single dose of VKA prior to randomization~* Participation in another pharmacotherapeutic study within the prior 30 days~* Creatinine clearance \< 30 mL/min, impaired liver function (transaminases \> 2 x ULN), or bacterial endocarditis~* Life expectancy \< 3 months~* Active bleeding or high risk for bleeding contraindicating treatment with (LMW) heparin~* Uncontrolled hypertension: systolic blood pressure \> 200 mmHg and diastolic blood pressure \> 110 mmHg~* Pregnancy or childbearing potential without proper contraceptive measures~* Any other contraindication listed in the labeling of warfarin, acenocoumarol, phenprocoumon, fluindione, UFH, enoxaparin, or tinzaparin~* Systemic treatment with azole compounds or other strong CYP3A4 inhibitors (e.g. ketoconazole, fluconazol, itraconazole, HIV protease inhibitors) within 4 days prior to randomization and during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 4 (Type: ACTIVE_COMPARATOR): None
- Arm 1 (Type: EXPERIMENTAL): None
- Arm 2 (Type: EXPERIMENTAL): None
- Arm 3 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Confirmatory Study to Assess the V Needle in End-Stage Renal Disease Patients During In-Clinic Hemodialysis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects with end-stage renal disease receiving chronic hemodialysis in a clinical setting.~2. Subjects must be able to receive hemodialysis with the Hemotek 15-gauge, 1 inch length V Needle, with 12 inch tubing.~3. Age greater than or equal to 22 years old at screening.~4. Vascular access via a mature arteriovenous (AV) fistula or graft in the arm and determined to be adequate for a chronic hemodialysis therapy.~5. AV fistula has already been demonstrated to adequately permit one or more hemodialysis sessions.~6. Subject prescribed blood flow rates between 200 ml/min and 450 ml/min~7. In women with child-bearing potential, negative urine or serum pregnancy test at Screening.~8. Subject able to communicate effectively with investigative staff, competent and willing to give written informed consent, and able to comply with entire study procedures.~9. Hemoglobin ≥9 g/dL (consistent with KDOQI guidelines)~10. Normal platelet count (≥150,000 /mm3)~11. International Normalized Ratio (INR) ≤ 1.5~Exclusion Criteria:~1. Subjects receiving chronic hemodialysis with a vascular catheter.~2. Subjects with vascular access that is determined by the clinician to be unacceptable for a hemodialysis procedure.~3. Patients with a bleeding diathesis~4. Patients receiving anti-coagulants~5. Previous vascular access surgery (≤30 days from study entry) or planned access surgery~6. Known hypersensitivity to any imaging agents (e.g., contrast) that may be required during the study period~7. Patients with confirmed vasculitis~8. Vascular access infection or systemic active infection within 30 days of study entry~9. Life expectancy less than 12 months~10. Planned renal transplantation or planned conversion to peritoneal dialysis~11. Subjects with any condition determined by the investigator that precludes them from safely participating in the study.

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of Care vs. V Needle Performance Assessment (Type: EXPERIMENTAL): Subjects will undergo three dialysis sessions using standard of care needles (control) and results will be compare to 6 dialysis sessions using the V Needle (experimental).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Endometrial Injury and Single Embryo Transfer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* woman age under 35 years~* history of primary infertility~* normoresponder (antral follicle count 5-10 in one ovary in early follicular phase~* having grade I or II embryos for transfer~* agree to undergo endometrial biopsy during the COH cycle. All patients were stimulated with luteal phase long protocol.~Exclusion Criteria:~* endocrinopathies (including diabetes mellitus, hyperprolactinemia, Cushing's disease, and congenital adrenal hyperplasia), any systemic disease, collagen disorder, hypercholesterolemia, sickle cell anemia, and a history of neoplasm; -high risk for or history of OHSS~* using any concurrent medication (e.g., insulin-sensitizing drugs, and GnRH antagonists)~* patients who did not proceed to follicle retrieval~* severe male infertility requiring TESA/TESA~* mullerian tract anomalies~* a history of endometrial instrumentation or surgery within a month of the study~* not agree to undergo endometrial biopsy during the COH cycle.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Endometrial injury (Type: EXPERIMENTAL): The patients in this group will be subjected to endometrial injury procedure in preceding IVF cycle.
- No endometrial injury (Type: NO_INTERVENTION): The patients in this group will not be subjected to endometrial injury procedure in presiding IVF cycle. The patients will be stimulated with standard IVF protocol.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: - Subjects fulfilling at least one of the below criteria: a) Experienced at least one severe hypo episode within the last year (according to the ADA (American Diabetes Association) definition, April 2013) b) Moderate chronic renal failure, defined as glomerular filtration rate 30 - 59 mL/min/1.73 m\^2 per CKD-Epi (chronic kidney disease epidemiology collaboration) c) Hypoglycaemic symptom unawareness d) Diabetes mellitus duration for more than 15 years e) Recent episode of hypoglycaemia (defined by symptoms of hypoglycaemia and/or episode with low glucose measurement (below or equal to 70 mg/dL \[below or equal to 3.9 mmol/L\])) within the last 12 weeks prior to Visit 1 (screening) - Male or female, age at least 18 years at the time of signing informed consent - Type 1 diabetes mellitus (diagnosed clinically) for at least 52 weeks prior to Visit 1 - Current treatment with a basal-bolus regimen consisting of neutral protamine Hagedorn (NPH) insulin OD (once daily) / BID (twice daily) or insulin detemir (IDet) OD / BID plus 2-4 daily injections of any rapid acting meal time insulin or CSII (with rapid acting insulin) for at least 26 weeks prior to Visit 1 - HbA1c (glycosylated haemoglobin) below or equal to 10% by central laboratory analysis - BMI (body mass index) below or equal to 45 kg/m\^2 Exclusion Criteria: - Treatment with IGlar or IDeg within the last 26 weeks prior to Visit 1 (short term use \[less than or equal to 2 weeks\] is allowed, but not within 4 weeks prior to screening) - Use of any other anti-diabetic agent than those stated in the inclusion criteria within the last 26 weeks prior to Visit 1

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IDeg OD + IAsp followed by IGlar OD + IAsp (Type: EXPERIMENTAL): Each treatment period consists of a 16-week wash-out period and a 16-week maintenance period
- IGlar OD + IAsp followed by IDeg OD + IAsp (Type: ACTIVE_COMPARATOR): Each treatment period consists of a 16-week wash-out period and a 16-week maintenance period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Psychometric Testing: Cued vs. Learned Suppression

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Normal or corrected-to-normal visual acuity, normal color vision~Exclusion Criteria:~* age

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Attention and Working Memory Tests (Type: EXPERIMENTAL): All participants will complete a series of behavioral tasks, including cued visual search with positive (target color), negative (distractor color) and neutral (baseline) cues, learned visual search with a repeated salient distractor color, a visual working memory capacity task, and a daily life inattentive traits questionnaire (self-report). Single Arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* \>= to 18 years of age~* Hypertension uncontrolled on current monotherapy~* Females:~* negative serum pregnancy test at screening~* post menopausal or have had a hysterectomy or tubal ligation or practicing approved methods of birth control~Exclusion Criteria:~* Pregnant females~* Uncontrolled hypertension with multiple drugs, except for hydrochlorothiazide/triamterene~* Diabetes requiring insulin~* Serious disorders that may limit the ability to evaluate the efficacy or safety of treatment~* History of myocardial infarction, bypass graft, angioplasty or heart failure within the past 6 months~* History of Class III or IV congestive heart failure~* History of stroke or transient ischemic attack within the last 1 year

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Azor tablets and hydrochlorothiazide tablets (if necessary) will be administered for up to 20 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Interaction Between Aspirin and Nexium

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provision informed consent prior to any study specific procedures.~* Healthy male and female subjects aged 18 to 75 years with suitable veins for cannulation or repeated vein puncture.~* Healthy female subjects must be of non-childbearing potential (post-menopausal, had a hysterectomy and/or bilateral oophorectomy) or be of childbearing potential and have a negative serum hCG pregnancy test during screening and be using of the following methods of birth control:~* Continuously practice abstinence during screening and throughout the duration of the study~* Clinically accepted contraception as described under item 7 of Section 5.1 and on hormonal contraceptives.~* Have a body mass index (BMI) between 19 and 30 kg/m2~* No clinically significant abnormal findings as judged by the Investigator on enrollment physical exam.~Exclusion Criteria:~* Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)~* Previous enrolment or randomisation in the present study.~* History of any clinically significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study e.g. history of any bleeding disorder, excessive bruising or ongoing or history of liver disease~* History or presence of clinically significant gastrointestinal e.e. GI ulcer, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs.~* Any clinically significant illness within 4 weeks of the first administration of investigational product.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Aspirin 81 mg
- 2 (Type: ACTIVE_COMPARATOR): Esomeprazole 20mg/aspirin 81mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria~Females age 18 years or older at the time of informed consent~Have histologically or cytologically proven adenocarcinoma of the breast~Subjects with locally recurrent or metastatic disease with at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors~(RECIST) criteria v 1.1~Human epidermal growth factor receptor (HER2)-negative disease as determined by fluorescence in situ hybridization (FISH) or 0 or 1+ by immunohistochemical (IHC) staining.~Life expectancy of greater than 24 weeks~Eastern Cooperative Oncology Group (ECOG) Performance Score (PS) of 0, 1 or 2~At least 12 months since prior neoadjuvant or adjuvant chemotherapy~At least 2 weeks since prior radiotherapy or endocrine therapy, with complete recovery from the effects of these interventions~Adequate renal function~Adequate bone marrow function~Adequate liver function~Key Exclusion Criteria~Subjects who meet any of the following criteria will be excluded from participation in this study:~Prior chemotherapy, biologic therapy, or investigational therapy for locally recurrent or metastatic breast cancer~Subjects who have had a prior malignancy other than carcinoma in situ of the cervix or nonmelanoma skin cancer~Prior exposure of greater than 360 mg/m2 doxorubicin or liposomal doxorubicin, greater than 120 mg/m2 mitoxantrone, greater than 90 mg/m2 idarubicin, or greater than720 mg/m2 epirubicin~Inflammatory breast cancer~Clinically significant cardiovascular impairment~Subjects with known CNS disease are not eligible, except for those with treated brain metastasis.~Pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring the use of oxygen~Currently pregnant or breast-feeding.~Subjects with pre-existing Grade 3 or 4 neuropathy. Any peripheral neuropathy must recover to Grade 2 before enrollment.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has had stable moderate to severe plaque psoriasis for at least 6 months~* Subject has received at least one previous phototherapy or systemic psoriasis therapy or has been a candidate to receive phototherapy or systemic psoriasis therapy in the opinion of the investigator.~* Subject has involved BSA ≥ 10% and PASI ≥ 12 at screening and at baseline.~Exclusion Criteria:~* Subject diagnosed with erythrodermic psoriasis, pustular psoriasis, medication-induced, or medication-exacerbated psoriasis.~* Evidence of skin conditions at the time of the screening visit (eg, eczema, guttate psoriasis) that would interfere with evaluations of the effect of IP on psoriasis.~* Subject has any active CTCAE grade 2 or higher infection~* Subject has a significant concurrent medical condition or laboratory abnormalities, as defined in the study protocol.~* Subject has used the following therapies within 14 days of the first dose: UVB therapy or topical psoriasis therapies other than Class I or II topical steroids~* Subject has used the following therapies within 28 days of the first dose: Class I or II topical steroids, UVA therapy (with or without psoralen), or systemic psoriasis therapies~* Subject has used the following therapies within 3 months of the first dose: adalimumab, alefacept, etanercept, infliximab, certolizumab, or live vaccines~* Subject has used an anti-IL12/IL23 inhibitor within 6 months of the first dose~* Subject has previously used an anti-IL17 biologic therapy, efalizumab, or rituximab

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 140 mg SC (Type: EXPERIMENTAL): 140 mg SC
- 70 mg SC (Type: EXPERIMENTAL): 70 mg SC
- 280 mg SC (Type: EXPERIMENTAL): 280 mg SC
- 210 mg SC (Type: PLACEBO_COMPARATOR): 210 mg SC
- Placebo (Type: EXPERIMENTAL): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vardenafil and Cognitive-behavioral Sex Therapy for the Treatment of Erectile Dysfunction (STEDOV)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* This study involved 30 male patients with ED, and their partners, both aged \> 18 years and in a stable heterosexual relationship (\> 6 months), seeking medical care for sexual dysfunction at Andrology Unit of University of Florence, Florence, Italy~Exclusion Criteria:~* Couples were excluded from participation if man had unstable medical conditions~* Prior pelvic surgery or trauma~* Spinal cord injury~* Prostate surgery or radiation~* Diabetes mellitus~* Neurogenic trauma~* Retinitis pigmentosa~* Peyronie's disease~* Multiple sclerosis~* Substance abuse disorder~* Significant mental health problems requiring psychotropic drugs, or were receiving medication for heart disease/angina (especially nitrates) or vascular disease.~* Testosterone levels has been considered normal for plasma levels ≥ 12 nmol/L and/or calculated free testosterone≥ 225 pmol/L.~* When a diagnosis of hypogonadism was made, an adequate testosterone replacement therapy was assessed.~* Patients with an artheriogenic ED (assessed with peak systolic velocity at penile colour doppler ultrasound after PGE1 stimulation, considered normal for data ≥ 25 cm/sec ) were excluded.~* We also excluded couples including women with primary sexual dysfunction, as dyspareunia, anorgasmia or vaginismus; substance abuse disorder and/or with significant mental health problems requiring psychotropic drugs.~* The presence of substance abuse or mental health problems was assessed by clinical interviews by a mental health specialist.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- vardenafil (Type: ACTIVE_COMPARATOR): The study includes a total period of 10 week with a total of 3 visits for vardenafil Group (at the beginning, at 5th week and at the end). In this study we used Vardenafil 10 mg orodispersible tablets. These are the only orodispersible tablets on commerce indicated for the treatment of ED. Male patients will begin taking Vardenafil 10 mg orodispersible tablets 2 times a week for 10 weeks.
- vardenafil+cbst (Type: ACTIVE_COMPARATOR): The study includes a total period of 10 week with a total of 10 visits for vardenafil+cbst Group (one weekly visit).~Male patients will begin taking Vardenafil 10 mg orodispersible tablets 2 times a week for 10 weeks.CBST interventions used in this study includes: psycho-educational interventions on ED maintaining, on anxiety's role and sexual homework. This course is structured in 10 weekly meetings.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete